Lilly Continues Buying Spree With Three Vaccine Firm Takeouts
Bringing it to 10 M&A transactions during the first five months of 2026, Lilly has agreed to acquire Curevo, LimmaTech and Vaccine Company for as much as $3.8bn, including earnouts.
Scrip - May 26, 2026

Finance Watch: Asia IPO Numbers Attempting To Catch Up With US Offerings
Public Company Edition: After three drug developer IPOs in Hong Kong and Korea in Q1, there have been three in Asia halfway through Q2, with HanchorBio listing in Taiwan soon. Also, RA Capital launched a SPAC, while Relay raised $275m and Immix grossed $150m in FOPOs.
Scrip - May 26, 2026

All Eyes On ABTECT After More Positive Data On Abivax’s Obefazimod
Analysts claim the French biotech is leading the oral IBD landscape and are waiting for a mega-deal centered on the miR-124 up-regulator.
Scrip - May 26, 2026

Pipeline Watch: Thirteen Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 26, 2026

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data
While early data for VERVE-102 mark another step in Lilly's push into cardiovascular gene editing, analysts question the need for a one-and-done therapy to lower LDL-C given existing treatment options.
Scrip - May 26, 2026

In Case You Missed It: ASCO Preview
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 26, 2026

Impact Of China’s New Data Protection On Corporate Strategies, Deals
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026

Jardine Matheson Acquires Australia’s I-MED Radiology In $2.4Bn Deal
Jardine's plunge into Australia's diagnostic imaging sector through the I-MED deal also grants it a minority stake in AI developer Harrison.ai.
Medtech Insight - May 26, 2026

Stryker Launches Pangea Plating System In Europe Two Years After US Debut
Stryker's Pangea Plating System has reached Europe, two years after its US debut. With its first clinical case completed in London, the platform now enters a $7.8bn trauma fixation market – and into a direct fight with DePuy Synthes, Zimmer Biomet and entrenched surgeon loyalties.
Medtech Insight - May 26, 2026

MHRA’s Premarket SI: Agency Foresees No Major WTO Roadblocks
MHRA’s Rob Reid spoke to Medtech Insight on UK and EU medtech regulatory progress after his panel on reliance at the MedTech Forum 2026.
Medtech Insight - May 26, 2026

NICE Says Advanced Liver-Preserving Devices Will Boost Transplant Equality
Four machine perfusion technologies have been recommended for routine NHS use in draft guidance that aims to address the liver transplant “postcode lottery.”
Medtech Insight - May 26, 2026

Mercury Rises As US Skin-Lightening Concern
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026

Irish CJEU Referral Offers Route To Challenge UWWTD
The Irish High Court’s referral to the CJEU of questions over the validity of the EU Urban Wastewater Treatment Directive’s extended producer responsibility scheme offers the off-patent industry another route to challenge the controversial legislation.
Generics Bulletin - May 26, 2026

Lupin Downs Otsuka On US Jynarque Appeal
Lupin has prevailed at the Federal Circuit in a patent dispute involving Otsuka’s Jynarque, preserving a non-infringement win and invalidating asserted tolvaptan synthesis claims.
Generics Bulletin - May 26, 2026

The Modernization Of Entity Matching: A Strategic Imperative For The Life Sciences Sector
The integration of advanced machine learning and generative AI into entity matching pipelines is increasingly recognized for its value in modernizing patient record linkage, unlocking real-world evidence, optimizing clinical trials and driving commercial success.
In Vivo - May 26, 2026

Against Specialist Tide, Anthropic Backs A Generalist Claude for Biopharma’s R&D Stack
Anthropic is betting that a generalist Claude trained on biology, backed by a $400m biotech acquisition, an in-house wet lab and a Novartis-CEO board seat, can become biopharma’s end-to-end AI partner for drug discovery.
In Vivo - May 26, 2026